Company profilePharmaceutical#959 of 1,318 in Pakistan✓ No DRAP alerts

RSK Pharmaceuticals

Pharmaceutical company · 4 brands · 4 molecules

4 registered products 5 pharmaceutical brands 4 distinct molecules 0 DRAP alerts

Company overview

4
registered products
5
pharmaceutical brands
4
distinct molecules
0
therapeutic classes
0
DRAP alerts

RSK Pharmaceuticals is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 4 product registrations across 4 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by RSK

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

3
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20263

Top molecules by brand count

Piperacillin2 brands
Piperacillin ...... 2 Gm1 brand
Piperacillin ...... 4 Gm1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official5 products · Rs 669.14 – Rs 2,105.84
Median across source: Rs 1,521.32

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Genix Pharma Private Limited holds 155 molecules not in this portfolio
000 I.UAceclofenacAcyclovirAlbendazoleAlfacalcidolAmikacin
Global Pharmaceuticals Pakistan holds 145 molecules not in this portfolio
AmikacinAmlodipineAmocycillinAmoxicillinAmoxicillin AmoxicillintrihydrateAmoxycillin
M/s Daneen Pharma (Pvt) Ltd holds 31 molecules not in this portfolio
AcyclovirArtemetherArtesunateAzithromycinCefiximeCeftazidime

Get the full profile for RSK

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.